NVS catalyst calendar

NOVARTIS AG

Upcoming catalysts
45
Cash runway
Cash generating
Cash & investments
$11590M
Phase 3 programs
70

NOVARTIS AG is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) on October 29, 2026. There are 45 upcoming events on record.

NOVARTIS AG generates cash from operations, so a burn-based runway figure does not apply.

Across 426 concluded trials, 79% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
October 29, 2026 Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) Trial Milestone Phase 3
November 3, 2026 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up Trial Milestone Phase 3
December 8, 2026 A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction Trial Milestone Phase 1
December 30, 2026 Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment Trial Milestone Phase 3
February 4, 2027 Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2) Trial Milestone Phase 2
February 22, 2027 A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines Trial Milestone Phase 3
February 26, 2027 Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation Trial Milestone Phase 3
February 26, 2027 Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer Trial Milestone Phase 2
March 23, 2027 Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults Trial Milestone Phase 2
April 9, 2027 Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer Trial Milestone Phase 1
April 12, 2027 Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) Trial Milestone Phase 3
April 30, 2027 A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. Trial Milestone Phase 3
June 2, 2027 An Extension Study for Patients Previously Enrolled in Studies With Pelabresib Trial Milestone Phase 3
June 9, 2027 Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study Trial Milestone Phase 4
August 10, 2027 A Study of Zigakibart in Adults With IgA Nephropathy Trial Milestone Phase 3
August 23, 2027 Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria Trial Milestone Phase 2
August 31, 2027 Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. Trial Milestone Phase 1
September 9, 2027 A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation Trial Milestone Phase 2
October 1, 2027 A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas Trial Milestone Phase 1/Phase 2
February 8, 2028 A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission Trial Milestone Phase 4
February 25, 2028 A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis Trial Milestone Phase 3
February 25, 2028 A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A. Trial Milestone Phase 1
March 7, 2028 A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab Trial Milestone Phase 1/Phase 2
April 25, 2028 An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. Trial Milestone Phase 3
May 4, 2028 Study to Assess Safety and Clinical Responses With Coartem® Baby Dispersible Tablets in Paediatric Patients Weighing 2 to <5 kg With Uncomplicated Malaria Trial Milestone Phase 4
May 15, 2028 An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis Trial Milestone Phase 1
May 24, 2028 Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks Trial Milestone Phase 3
June 19, 2028 A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS Trial Milestone Phase 1
September 14, 2028 A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease Trial Milestone Phase 2
October 27, 2028 Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN Trial Milestone Phase 3
November 27, 2028 Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis Trial Milestone Phase 2
November 30, 2028 ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS Trial Milestone Phase 4
December 26, 2028 A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period Trial Milestone Phase 2
December 30, 2028 A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. Trial Milestone Phase 3
July 16, 2029 An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD) Trial Milestone Phase 2
August 21, 2029 A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Trial Milestone Phase 2
October 31, 2029 Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA). Trial Milestone Phase 1
January 29, 2030 Secukinumab Open Label Roll-over Extension Protocol Trial Milestone Phase 4
June 3, 2030 A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer Trial Milestone Phase 1
August 30, 2030 Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab Trial Milestone Phase 2
December 3, 2030 A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis Trial Milestone Phase 3
December 30, 2030 Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral Anticoagulation Trial Milestone Phase 3
May 28, 2031 DFT383 in Pediatric Participants With Nephropathic Cystinosis Trial Milestone Phase 1/Phase 2
May 30, 2036 Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN Trial Milestone Phase 3
January 11, 2039 Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC) Trial Milestone Phase 1

Track NVS alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open NVS in the tracker

Recent history

DateEventTypePhase
September 30, 2026 Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation Trial Milestone Phase 1/Phase 2
September 8, 2026 6-K filed: Foreign issuer report Filing —
September 4, 2026 6-K filed: Foreign issuer report Filing —
September 3, 2026 Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer Trial Milestone Phase 3
September 3, 2026 Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease Trial Milestone Phase 4
September 1, 2026 6-K filed: Foreign issuer report Filing —
July 30, 2026 Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants Trial Milestone Phase 1
July 21, 2026 6-K filed: Foreign issuer report Filing —
June 11, 2026 6-K filed: Foreign issuer report Filing —
June 9, 2026 Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria Trial Milestone Phase 2
May 12, 2026 A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa Trial Milestone Phase 1/Phase 2
April 28, 2026 6-K filed: Foreign issuer report Filing —
March 18, 2026 6-K filed: Foreign issuer report Filing —
February 25, 2026 Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI) Trial Milestone Phase 2
February 13, 2026 DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies Trial Milestone Phase 1
February 4, 2026 Results filed (20-F) Earnings —
February 4, 2026 6-K filed: Foreign issuer report Filing —
February 4, 2026 6-K filed: Foreign issuer report Filing —
December 1, 2025 A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease. Trial Milestone Phase 4
November 25, 2025 6-K filed: Foreign issuer report Filing —
November 20, 2025 6-K filed: Foreign issuer report Filing —
November 5, 2025 6-K filed: Foreign issuer report Filing —
October 28, 2025 6-K filed: Foreign issuer report Filing —
October 27, 2025 6-K filed: Foreign issuer report Filing —
October 14, 2025 Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations Trial Milestone Phase 2
September 30, 2025 6-K filed: Foreign issuer report Filing —
August 11, 2025 6-K filed: Foreign issuer report Filing —
August 4, 2025 Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC. Trial Milestone Phase 4
July 24, 2025 To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria Trial Milestone Phase 2
July 17, 2025 6-K filed: Foreign issuer report Filing —

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.